GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Return-on-Tangible-Equity

Apyx Medical (Apyx Medical) Return-on-Tangible-Equity : -129.08% (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Apyx Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Apyx Medical's annualized net income for the quarter that ended in Mar. 2024 was $-30.30 Mil. Apyx Medical's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $23.48 Mil. Therefore, Apyx Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -129.08%.

The historical rank and industry rank for Apyx Medical's Return-on-Tangible-Equity or its related term are showing as below:

APYX' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -157.12   Med: -25.36   Max: 115.13
Current: -74.55

During the past 13 years, Apyx Medical's highest Return-on-Tangible-Equity was 115.13%. The lowest was -157.12%. And the median was -25.36%.

APYX's Return-on-Tangible-Equity is ranked worse than
80% of 760 companies
in the Medical Devices & Instruments industry
Industry Median: 1.395 vs APYX: -74.55

Apyx Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Apyx Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apyx Medical Return-on-Tangible-Equity Chart

Apyx Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.88 -17.63 -25.84 -50.79 -58.22

Apyx Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.84 -10.95 -52.95 -127.99 -129.08

Competitive Comparison of Apyx Medical's Return-on-Tangible-Equity

For the Medical Devices subindustry, Apyx Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apyx Medical's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Apyx Medical's Return-on-Tangible-Equity falls into.



Apyx Medical Return-on-Tangible-Equity Calculation

Apyx Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-18.713/( (37.582+26.701 )/ 2 )
=-18.713/32.1415
=-58.22 %

Apyx Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-30.304/( (26.701+20.253)/ 2 )
=-30.304/23.477
=-129.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Apyx Medical  (NAS:APYX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Apyx Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Apyx Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Apyx Medical (Apyx Medical) Business Description

Traded in Other Exchanges
Address
5115 Ulmerton Road, Clearwater, FL, USA, 33760
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Executives
Todd Hornsby officer: Executive Vice President 14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine director 75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb officer: Chief Financial Officer 5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal director 5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty director 1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman director 5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres director 86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers officer: Chief Financial Officer 4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron director, officer: President
Robert Gershon director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii officer: Chief CommercializationOfficer 23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson director C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz officer: Vice President of Operations

Apyx Medical (Apyx Medical) Headlines

From GuruFocus

Chuck Royce Adds Apyx Medical Corp to Portfolio

By GuruFocus Research 01-24-2024